文献速递技术与安全MR

磁共振对比剂领域当前的研究与开发进展

Current Research and Development in the Field of Magnetic Resonance Contrast Media.
PubMed 文献 · Invest Radiol · 2025-11-01

本文讨论下一代高弛豫率钆基对比剂(钆匹醇和钆夸曲胺)及其安全性研究、MR技术改进和新药剂开发;在七国集团国家,线性钆螯合物因相对不稳定性和组织沉积问题已基本停止使用;锰基化合物重新进入研究视野,人工智能和深度学习在MR对比剂中的应用也日渐成熟。

要点

  • 下一代高弛豫率钆基对比剂钆匹醇和钆夸曲胺可能将大范围取代当前标准的宏环钆螯合物。
  • 七国集团国家因线性钆螯合物相对不稳定及注射后钆在脑和骨等组织沉积的担忧,已基本停止使用线性钆螯合物。
  • 锰基化合物重新被研究,但其对临床影像的潜在影响尚不明确。

核心结论

  • 下一代高弛豫率钆基对比剂钆匹醇和钆夸曲胺可能将大范围取代当前标准的宏环钆螯合物,尽管后者安全性极佳且稳定性很高。

研究设计与样本

  • 本文为综述,讨论下一代高弛豫率钆基对比剂、安全性新研究、MR技术改进及其他药剂的持续开发。

局限性

  • 锰基化合物对临床影像的潜在影响尚不明确。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The next-generation, high relaxivity, gadolinium-based contrast agents (GBCAs) are discussed, together with new studies of safety, improvements in MR technique, and the ongoing development of additional agents. It is likely that the next generation agents, gadopiclenol and gadoquatrane, will largely replace the current standards, the macrocyclic gadolinium chelates, despite the excellent safety profile and very high stability of the latter. In the Group of Seven (G7) nations, which includes Canada, France, Germany, Italy, Japan, the United Kingdom and the United States, use of the linear gadolinium chelates has largely ceased, due to concerns regarding their relative instability as compared to the macrocyclic agents and the deposition of gadolinium that occurs in many tissues, including brain and bone, following their injection. Manganese-based compounds are once again being investigated, a field largely untouched since the initial development of clinical MR contrast media in the 1980s. Their potential impact on clinical imaging is, however, unclear. New information continues to emerge regarding differences in stability of the gadolinium-based agents. Artificial intelligence and deep learning techniques are maturing and are discussed briefly, given their potential and recent clinical application involving MR contrast media.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Runge VM. Current Research and Development in the Field of Magnetic Resonance Contrast Media. Invest Radiol. 2025. PMID: 40622723. doi:10.1097/RLI.0000000000001206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。